Laurus Labs Ltd management interview: Laurus Labs Stake Sale Done To Pay Off Debt & Philanthropy Purposes, Clarifies Satyanarayana Chava
CNBC-TV18, 2026-11-17. Video: https://www.youtube.com/watch?v=L9j575ysGCQ
- Promoter stake sale: Chava said the sale of around 20 lakh shares was used to retire debt, provide liquidity and support philanthropy. His stake rose from 21.7% at IPO to 23%; he said promoters have no plans to buy or sell shares at this point.
- CDMO outlook: Management expects CDMO to reach at least 50% of the business by FY30, with gross margins and EBITDA margins remaining at similar levels or rising over the coming several quarters. Chava said the business is not peaking and expects growth from the current pipeline.
- Capex and returns: Capex for FY27 is expected to be close to ₹2,000 crore, with investment in FY28 potentially taking the total beyond ₹3,000 crore; the next year’s capex may be closer to ₹1,500-2,000 crore. It will be funded internally, net debt to EBITDA is 1, and management expects to maintain or increase return ratios.
- Peptide capacity: Laurus has commissioned around 16 kL of peptide capacity, has programs in Phase II and Phase III, and plans further expansion; validations will happen next year. Chava said the business will be margin and EBITDA accretive, but did not disclose customers or project names.
- Business visibility: Current revenue of between ₹800 and ₹900 crore has visibility and is not dependent on approvals; additional clinical programs could add opportunity. Laurus says it can offer integrated CDMO solutions from starting materials through API and drug product, and management sees reasonable growth ahead over the next 5 years.